Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
16 dec 2014 - 07:30
Statutaire naam
Galapagos NV
Titel
Galapagos regains full rights to GPR84 inhibitor GLPG1205
Bericht
Program to enter first Phase 2 patient study in ulcerative colitis this month
Mechelen, Belgium; 16 December 2014 - Galapagos NV (Euronext: GLPG) announced today it has agreed with Janssen Pharmaceutica NV that Galapagos will regain full and unencumbered rights to the entire GPR84 program going forward, which includes the inhibitor GLPG1205 and its backup compound GLPG2196. No further details were disclosed.
Datum laatste update: 16 maart 2026